BIIB BIOGEN INC. Insider Trading

Murphy Nicole (Head of Pharm Ops and Tech) bought 3 shares of BIIB at $195.04 on 2026-02-12.

Murphy Nicole's purchase of 3 shares represents a net change of +0.0% to her existing holdings of 19,611 shares, reflecting a minimal transaction in absolute and relative terms. The stock has appreciated 19.0% over the past 30 days and 16.5% over 90 days, trading near its 52-week high at $195.62 (down only 2.8% from the 52-week peak of $201.18). BIOGEN's fundamentals show stable operational metrics with $2.5B quarterly revenue and net income of $466.5M, though annual revenue growth is modest at +2.2%. The transaction's immaterial scale and negligible portfolio impact provide limited signaling value regarding insider conviction or strategic positioning.

Director Dorsa Caroline purchased 1,235 shares of BIIB at $122.72 on 2025-05-02, increasing holdings to 27.8K shares. Stock down 48.6% from 52-week high.

Director Dorsa Caroline bought 1,235 shares at $122.72, adding 4.6% to prior holdings of 26.6K shares at a time when BIIB trades at $121.80 (current), down significantly from its 52-week high of $236.80 and down 14.5% over the past 90 days. The purchase occurs amid modest fundamental metrics: P/E of 12.06 on annual revenue of $2.4B with net income of $240.5M, while the company faces year-over-year revenue decline of -1.6%. The transaction represents an open-market purchase by a director and provides a factual data point on insider positioning during a period of material stock decline, though the modest share quantity and single-transaction nature limit broader inference about insider conviction across the company.

Director Sherwin Stephen A sold 8,760 shares of BIIB at $150.02 for $1,314,141.91; stock down -36.4% from 52-week high, P/E 10.58.

Sherwin Stephen A sold 8,760 shares on 2025-03-07, reducing his holdings by -43.6% from 20,078 to 11,318 shares at a price of $150.02. The stock is currently trading 30-day change: +6.6% and 90-day change: -3.6%, down -36.4% from its 52-week high of $236.80. Across his cross-ticker track record, his prior sells averaged a 90-day return of +14.3%, meaning the stock typically rose after he sold, which reflects poorly-timed exits historically. At the current valuation (P/E 10.58, revenue growth -1.6% annually), the sale occurs with BIIB trading significantly below recent highs and at modest profitability multiples. The substantial reduction in stake (43.6%) warrants observation of whether this reflects portfolio reallocation or changed conviction at BIIB specifically.